title: Infliximab reduces the number of activated mucosal lymphocytes in patients with Crohn's disease.
abstract: BACKGROUND
  Infliximab is an effective treatment for Crohn's disease in patients with poor prior response to conventional therapy. The mechanism by which infliximab induces clinical improvement is not completely known.
  
  
  OBJECTIVE
  The aim of the study was to investigate the influence of infliximab on immunological parameters in peripheral blood and inflamed intestinal mucosa.
  
  
  METHODS
  Twenty-five patients with Crohn's disease (11 with luminal and 14 with fistular form) underwent treatment with infliximab. The lymphocyte populations from the peripheral blood and the inflamed intestinal mucosa were analysed by flow cytometry before treatment and 14 days later.
  
  
  RESULTS
  After treatment, the peripheral blood analysis showed a significant increase in the percentage of CD19 cells and the concentrations of CD3, CD4, CD8 and activated (HLA DR positive) T cells, while the percentage of NK cells was reduced. In the inflamed mucosa, a significant decrease in the percentage of activated T cells and expression of HLA I molecules by epithelial cells was noted.
  
  
  CONCLUSIONS
  Infliximab profoundly downregulates inflammation in the intestinal mucosa of patients with Crohn's disease. This effect is manifested by a reduction of activated T cells, main producers of proinflammatory cytokines, in the inflamed mucosa.
authors.affiliation: University Medical Centre, Division of Internal Medicine, Department of Gastroenterology, Japljeva 2, 1000 Ljubljana, Slovenia. ivan.ferko@Kclj.si
authors.forename: Ivan
authors.initials: I
authors.lastname: Ferkolj
authors.forename: Alojz
authors.initials: A
authors.lastname: Ihan
authors.forename: Sasa
authors.initials: S
authors.lastname: Markovic
authors.forename: Zeljka
authors.initials: Z
authors.lastname: Veceric
authors.forename: Maja
authors.initials: M
authors.lastname: Pohar
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D003424:Crohn Disease / Q000276:immunology* / Q000473:pathology*; D005260:Female; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D006801:Humans; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology; D008213:Lymphocyte Activation / Q000187:drug effects*; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab